Subject has received bevacizumab (Avastin).

Subjecting has any condition, including compromised pulmonary function, that would preclude the use of lomustine.

Subject is currently being treated with other investigational agents.

Subject has received other investigational therapy within the last 28 days.

Subject has received surgery within the last four weeks.

Subject is within 12 weeks of completion of radiation.

Subject has an active implantable or other electromagnetic device.

Subject has a metal implant, including a programmable shunt, in the head or neck that is incompatible with MRI.

Subject is known to be HIV positive.

Subject is pregnant, nursing or intends to become pregnant during the course of the study.

A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)